NCT00324623View on ClinicalTrials.gov

Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma

PHASE1CompletedINTERVENTIONAL
Enrollment

8

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

November 30, 2011

Conditions
Melanoma (Skin)
Interventions
BIOLOGICAL

Melan-A VLP vaccine, IMP321 adjuvant

BIOLOGICAL

adoptive immunotherapy

BIOLOGICAL

therapeutic autologous lymphocytes

DRUG

cyclophosphamide

DRUG

fludarabine phosphate

Trial Locations (1)

CH-1011

Centre Hospitalier Universitaire Vaudois, Lausanne

All Listed Sponsors
lead

Prof. Serge Leyvraz

OTHER

NCT00324623 - Cyclophosphamide and Fludarabine Followed by Cellular Adoptive Immunotherapy and Vaccine Therapy in Patients With Metastatic Melanoma | Biotech Hunter | Biotech Hunter